Hypericum perforatum (St John's Wort) for attention-deficit/hyperactivity disorder in children and adolescents: A randomized controlled trial

JAMA

Volumn 299, Issue 22, 2008, Pages 2633-2641

  Weber, Wendy ^a,e   Vander Stoep, Ann ^b,c   McCarty, Rachelle L ^a   Weiss, Noel S ^c   Biederman, Joseph ^d   McClellan, Jon ^b  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STRUCTURED INTERVIEW; SUNBURN; WEIGHT GAIN; HYPERICUM; PHYTOTHERAPY;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERICUM; MALE; PHYTOTHERAPY;

EID: 44949084636     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.22.2633     Document Type: Article

References (40)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170.
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
3. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? a meta-analysis. CMAJ. 2001;165(11):1475-1488.
4. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46(5):977-992.
5. Cala S, Crismon ML, Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy. 2003;23(2):222-230.
6. Bussing R, Zima BT, Gary FA, Garvan CW. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiatr Serv. 2002;53(9):1096-1102.
7. Stubberfield T, Parry T. Utilization of alternative therapies in attention-deficit hyperactivity disorder. J Paediatr Child Health. 1999;35(5):450-453.
8. Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002;23(1)(suppl):S37-S45.
9. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24(1):4-8.
10. Kasper S, Gastpar M, Muller WE, et al. Efficacy of St John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci. 2008;258(1):59-63.
11. Linde K, Mulrow CD, Berner M, Egger M. St John's wort for depression. Cochrane Database Syst Rev. 2005;(2):CD000448.
12. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-1814.
13. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-1986.
14. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine [published correction appears in BMJ. 2005;330(7494):759]. BMJ. 2005;330(7490):503.
15. Hübner WD, Kirste T. Experience with St John's wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res. 2001;15(4):367-370.
16. Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry. 2003;42(8):908-914.
17. Müller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30(suppl 2):102-107.
18. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004;7(1):77-97.
19. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.
20. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-1147.
21. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-1901.
22. DuPaul G, Power T, Anastopoulos A, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
23. National Institute of Mental Health. Clinical global impressions. Psychopharmacol Bull. 1985;21(4):839-843.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1995.
25. Orvaschel H, Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School Age Children-Epidemiologic Version (K-SADS-E). 4th ed. Pittsburgh, PA: Western Psychiatric Institute & Clinic; 1987.
26. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500-1504.
27. Kalachnick J. Assessment sheet for Monitoring of Side-Effects System (MOSES). In: Poling A, Gadow K, Cleary J, eds. Drug Therapy for Behavior Disorders: An Introduction. New York, NY: Pergamon Press; 1986:153-155.
28. Michelson D, Faries D, Wernicke J, et al. Atom-oxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
29. US Census Bureau. American Fact Finder. http://factfinder.census.gov/ home/saff/main.html?_lang=en. Accessed October 29, 2007.
30. Stata/SE [computer program]. Version 10.0. College Station, TX: StataCorp; 2007.
31. Achenbach T, Rescorla L. Manual for the ASEBA School Age Forms and Profiles. Burlington, VT: Achenbach System of Empirically Based Assessment; 2001.
32. Conners K. Conners' Rating Scales-Revised User's Manual. New York, NY: Multi-Health Systems Inc; 1997.
33. Varni JW, Seid M, Kurtin PS. The PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales in healthy and patient populations. Med Care. 2001;39(8):800-812.
34. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-e8.
35. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/ hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23(2):379-394.
36. Robison LM, Sclar DA, Skaer TL, Galin RS. Treatment modalities among US children diagnosed with attention-deficit hyperactivity disorder: 1995-99. Int Clin Psychopharmacol. 2004;19(1):17-22.
37. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857-864.
38. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2007;119(suppl 1):S99-S106.
39. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2002;109(3):E39.
40. Orth HC, Rentel C, Schmidt PC. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J Pharm Pharmacol. 1999;51(2):193-200.